Interested in upcoming stock listings? Read about the companies expected to go public in the US this year and see some of the most recent US listings. You'll also learn how IPO trading works and how to buy IPO stocks.


Last updated: November 20, 2026
Our 2026 IPO calendar includes the companies that’ve either formally announced plans to go public or filed documents with the Securities and Exchange Commission (SEC). Keep in mind that a company can file for an IPO without completing it, so a filing doesn't guarantee that shares will begin trading.
There are currently no upcoming IPOs featured in this calendar. We'll update it as further noteworthy listings are confirmed.
The table below highlights some of the recently listed IPO stocks. It's not a complete list of all the companies that went public in 2026.
Ticker | Exchange | First trading date | IPO offer price | |
Anthropic | ANT | Nasdaq | Nov 19, 2026 | $83 |
Lycia Therapeutics | LYCA | Nasdaq | Oct 23, 2026 | $18 |
City Therapeutics | CTY | Nasdaq | Oct 16, 2026 | $18 |
Iambic Therapeutics | IAM | Nasdaq | Oct 15, 2026 | $16 |
TRex Bio | TRXB | Nasdaq | Oct 9, 2026 | $14 |
Accelevation Holdings | ACCV | Nasdaq | Sep 30, 2026 | $18 |
ADARx Pharmaceuticals | ADRX | Nasdaq | Sep 25, 2026 | $17 |
Anthropic is the artificial intelligence (AI) company behind Claude, a family of AI models used by individuals and businesses. Its products include subscription-based AI assistants and models that developers can access to build their own applications.
ANT’s IPO involved approximately 980 million shares, including 956.4 million sold by the company and 23.6 million sold by existing shareholders. The offering was worth approximately $81.3 billion before expenses.
On its first trading day, Anthropic shares opened at $111.50 and closed at $97.17, approximately 17% above the IPO offer price.
Lycia Therapeutics develops treatments specifically for autoimmune diseases (with research focusing on Graves’) and food allergies. Its technology is designed to remove specific disease-causing proteins from the body, rather than simply blocking their activity.
It offered 17.64 million shares to the public upon listing and raised approximately $317.5 million (before underwriting costs and other expenses).
City Therapeutics develops medicine using a technology called RNA interference (RNAi), which works by reducing the production of proteins linked to certain diseases. Its research focuses on conditions such as blood-clotting disorders, inherited eye diseases and anemia.
Its IPO raised approximately $230 million before expenses, including the sale of additional shares by the underwriters.
Iambic Therapeutics combines AI with laboratory research to develop new medicines. This technology helps scientists predict how potential drug compounds might behave before testing them. The company focuses on cancer treatments.
Iambic released 9.375 million shares when it listed and received about $150 million before expenses.
TRex Bio develops treatments for autoimmune and inflammatory diseases, with a focus on how the immune system behaves in different tissues. Its research examines regulatory T cells, which help control immune responses and prevent excessive inflammation.
It offered approximately 8.33 million shares and raised $116.7 million before expenses.
Accelevation Holdings designs and manufactures equipment used in data centers, like cooling systems and structural components that support the computer servers. It also provides installation and maintenance services, helping clients build and upgrade the facilities they need to power cloud computing and AI.
The IPO involved 30 million shares worth $540 million. The company sold 10 million shares, while existing shareholders sold the remaining 20 million, so not all proceeds went to Accelevation.
ADARx Pharmaceuticals develops medicines that target RNA. Its technology aims to reduce the production of specific proteins involved in disease without permanently changing a person's DNA. The company is currently researching treatments for kidney conditions and hereditary angioedema.
ADARx sold approximately 30.19 million shares, raising $513.2 million before expenses, including additional shares sold after the initial offering.
When a company goes public, it offers shares to investors through an IPO. The company works with financial firms called underwriters to help set the offer price, organize the sale and distribute shares to investors.
Before trading begins, the company announces its final IPO price. Shares are then allocated to participating investors, which may include large institutions and eligible individual investors. Keep in mind that the IPO offer price is the initial share price set by the company, not necessarily the exact price investors paid once public trading began.
Once the stock starts trading on an exchange, investors can buy and sell shares. The actual share price is determined by buyers and sellers in the market, so it can be higher or lower than the original IPO offer price. Newly listed stocks can experience sharp price movements as investors react to the listing and the number of shares available for trading..
When a company sells new shares through an IPO, it receives the money raised from those sales. After the IPO, investors can buy and sell those shares on the stock market, with the money going to whoever sells them.
You can buy IPO stocks after they’ve listed through a brokerage that provides access to shares. Some brokerages offer access to IPO allocations before a stock lists, while others only support trading once shares become publicly available.
Here's how to get started:
Monitor your position. Once your order is filled, you can view your position and track its market value in your account.
Pre-IPO investing involves buying shares in a company before they become available on a public stock exchange. These transactions take place in private markets and can involve restrictions on who can invest, when shares can be sold and how ownership is transferred.
Buying private shares isn't the same as receiving an IPO allocation. Private shareholders already own shares before a listing, while an IPO allocation provides access to shares through the public offering. Neither guarantees that a company will successfully complete its IPO.
Eligible US users can buy and sell more than 12,000 stocks and exchange-traded funds (ETFs) through the Crypto.com App, with zero trading commissions.* Visit Crypto.com Stocks to learn more about available stocks and trading features.
You can check upcoming IPO dates through online IPO calendars, company investor relations pages and SEC filings, to name a few. Official company announcements and exchange notices can confirm listing details. Remember, a registration statement can provide an estimated schedule, but the actual listing date can change before trading begins.
Yes, an IPO can be delayed, rescheduled or even withdrawn before shares begin trading. A company's registration filing doesn't guarantee that the offering will proceed.
There are two ways to buy IPO shares: Through an IPO allocation before trading begins or through a brokerage after the stock lists. IPO allocations are subject to availability and your individual eligibility. Once public trading starts, you can place orders through a brokerage that supports the stock.
Pre-IPO investing involves buying private company shares before a public listing. These shares may be difficult to sell and can be subject to investor eligibility requirements and transfer restrictions. An IPO allocation provides access to shares through the public offering process. Buying shares after listing takes place on the public stock market.
Yes, eligible US users can trade stocks through the Crypto.com App once they're listed and available on the platform. Crypto.com Stocks also offers an early-order feature for eligible IPO stocks, subject to availability and applicable terms.
* Other fees may apply.
This content is for informational and educational purposes only and does not constitute financial, investment, or legal advice. IPO details are subject to change. Investing in stocks involves risk, including the possible loss of principal. Stock prices can be volatile, particularly when trading begins after an IPO. Product availability and eligibility restrictions apply.
Foris Capital US LLC (“FCUL” or referred to herein as “Crypto.com Stocks”) is a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a Member of the Financial Industry Regulatory Authority (FINRA) and the Securities Investor Protection Corporation (SIPC). For further information about FCUL, please visit FINRA BrokerCheck.
FCUL is a subsidiary of Crypto.com.
All investments involve risk, and not all risks are suitable for every investor. The value of securities may fluctuate and as a result, clients may lose more than their original investment. Past performance does not guarantee future results.